If you have been reading about Quality control and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Glutathione supports detoxification by conjugating reactive electrophiles through glutathione S-transferases. The resulting conjugates are processed and exported, often after further metabolism. It also stores cysteine, transports amino acids across membranes through the gamma-glutamyl cycle, and assists in the maturation of iron-sulfur clusters and some prostaglandins. In plants, animals, and many microbes, the molecule appears in similar roles, but concentrations vary enormously between tissues. Liver, kidney, and red blood cells tend to contain high amounts, while blood plasma contains much less.
Glutathione is a small tripeptide built from glutamate, cysteine, and glycine. The peptide bond between glutamate and cysteine uses the gamma-carboxyl group, a linkage that resists ordinary peptidases. Cells make it in two ATP-dependent steps: gamma-glutamylcysteine synthetase joins glutamate and cysteine, then glutathione synthetase adds glycine. The pathway is feedback-inhibited by glutathione itself, so intracellular levels tend to stay within a narrow range. Because cysteine is often limiting, sulfur amino acid supply influences how much glutathione a cell can produce.
In its reduced form, glutathione carries a sulfhydryl group that can donate electrons. This property lets it act as a major cellular antioxidant and redox buffer. Glutathione peroxidase uses it to reduce hydrogen peroxide and lipid peroxides, while glutathione reductase regenerates the reduced form using NADPH. The ratio of reduced glutathione to glutathione disulfide is widely used as an indicator of oxidative stress, though the ratio changes with compartment, cell type, and sample handling. Oxidized glutathione can also form mixed disulfides with proteins, affecting their activity.
For solid glutathione, storage conditions affect shelf life. The reduced form is typically kept cool, dry, and protected from air and light. Moisture can promote oxidation, while elevated temperatures accelerate degradation. Suppliers often specify storage at or below freezing, sometimes under inert gas. Solutions are less stable than powders and may require preparation shortly before use. Buffers and chelating agents can slow oxidation, but they do not eliminate it. Published stability data vary with matrix, pH, and container.
Quality control for glutathione focuses on identity, purity, and oxidation state. Certificates of analysis may report assay value, water content, and the presence of GSSG or other impurities. Chromatographic purity is often expressed as a percentage of peak area. Reference standards help laboratories compare results across instruments and batches. Because glutathione is a small, polar molecule, separation from cysteine, gamma-glutamylcysteine, and related thiols can be challenging. Verification often combines more than one analytical technique.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C10H17N3O6S | Refers to the reduced form |
| Molar mass | 307.32 g/mol | Calculated for the neutral molecule |
| Appearance | White crystalline powder | Often hygroscopic; protect from moisture |
| Water solubility | Soluble in water | Reported values vary with purity and form |
| Alternative names | GSH, reduced glutathione | GSH specifies the thiol form |
Interpreting glutathione measurements requires attention to pre-analytical variables. The GSSG concentration in a sample can rise artificially during storage or processing, making the GSH/GSSG ratio unreliable if not controlled. Reference ranges vary by specimen type, assay, and population, so comparisons across studies are difficult. Plasma glutathione is low and sensitive to hemolysis, while whole blood reflects primarily erythrocyte content. Many studies measure total glutathione rather than the reduced and oxidized forms separately, which limits conclusions about redox status.
Accurate measurement of glutathione begins with careful sample handling. Because GSH oxidizes rapidly to GSSG, samples must be processed quickly or frozen immediately. Acid precipitation with metaphosphoric acid or perchloric acid is common; it lowers pH, precipitates proteins, and helps preserve the reduced form. Chelating agents such as EDTA can limit metal-catalyzed oxidation. For whole blood, hemolysis releases glutathione from erythrocytes, so plasma and serum values differ substantially from whole blood values.
Quality control for glutathione materials checks identity, assay, purity, water content, and disulfide content. Commercial products vary from research-grade powder to dietary supplements, and labels may not distinguish reduced from oxidized forms. In the United States, oral glutathione is commonly sold as a dietary supplement rather than an approved drug, while injectable forms fall under different rules and may require a prescription. Regulatory status differs by country. Analytical certificates, when available, help verify what a material contains, but independent testing remains important for interpretation.
Laboratory measurement of glutathione typically starts with rapid acid extraction to prevent oxidation and enzymatic degradation. Common methods include enzymatic recycling assays, high-performance liquid chromatography, and liquid chromatography coupled with mass spectrometry. The recycling assay uses glutathione reductase and a thiol-reactive colorimetric or fluorescent reagent, measuring total glutathione after converting disulfide forms. Chromatographic methods can separate reduced and oxidized forms, which helps when the redox ratio is the target. Choice of method affects sensitivity, specificity, and the amount of sample needed.
The trust's executive directors discussed involving the police but instead commissioned a review by the Royal College of Paediatrics and Child Health (RCPCH). Letby was taken off the unit on 30 June, and the hospital subsequently reduced cot capacity and raised the gestational‑age threshold for admissions. The RCPCH review began in September 2016. Its October report found no definitive explanation for the increased mortality rate but identified inadequate staffing and senior cover. It described concerns about Letby as subjective and unsupported by evidence. The trust's medical director asked consultant neonatologist Jane Hawdon to undertake detailed case reviews recommended by the RCPCH. Hawdon instead conducted a review of medical notes relating to 17 deaths and collapses; she was understood to have told the hospital's medical director that she had not been able to conduct the thorough review that the RCPCH had recommended due to not having had the time, and later said that she had not been "adequately briefed" about the concerns about Letby before she carried out her analysis. The report concluded that most of the deaths and collapses could be explained and might have been preventable with different care, while four warranted further local forensic review. Minutes of a subsequent board meeting recorded the medical director stating that the RCPCH and Hawdon reviews attributed the deaths to leadership and intervention issues; the board chair later said he had been misled about the depth of Hawdon's review.
=== Dendritogenesis === Local interaction of BDNF with the TrkB receptor on a single dendritic segment is able to stimulate an increase in PSD-95 trafficking to other separate dendrites as well as to the synapses of locally stimulated neurons. PSD-95 localizes the actin-remodeling GTPases, Rac and Rho, to synapses through the binding of its PDZ domain to kalirin, increasing the number and size of spines. Thus, BDNF-induced trafficking of PSD-95 to dendrites stimulates actin remodeling and causes dendritic growth in response to BDNF.
Following increased criticism by Colombian President Gustavo Petro over US strikes on vessels and support for Israel in the Gaza war during his visit to the September session of the UN General Assembly, the US Department of State revoked Petro's visa on 27 September, stating on X that: "Earlier today, Colombian president (Gustavo Petro) stood on a NYC street and urged US soldiers to disobey orders and incite violence." Petro stated that a US airstrike had killed a Colombian fisherman whose vessel was not involved in drug trafficking, and accused the US of murder. Trump responded calling Petro an "illegal drug leader", who was "low rated" and not helping diminish production of drugs, stating that the US would end the large subsidies it provided to Colombia. In October 2025, the United States Department of the Treasury announced sanctions against Petro and Interior Minister Armando Benedetti, citing their alleged involvement in illicit drug trafficking activities. These measures marked a significant deterioration in bilateral relations, with the Colombian government condemning the decision as politically motivated and labeling it "an act of aggression" against its sovereignty. Analysts described the move as one of the most severe diplomatic escalations between Bogotá and Washington in recent years.
== History == DART resulted from conversations between Laramee and Cody about the development of an atmospheric pressure ion source to replace the radioactive sources in handheld chemical weapons detectors. DART was developed in late 2002 to early 2003 by Cody and Laramee as a new atmospheric pressure ionization process, and a US patent application was filed in April 2003. Although the development of DART actually predated the desorption electrospray ionization (DESI) ion source, the initial DART publication did not appear until shortly after the DESI publication, and both ion sources were publicly introduced in back-to-back presentations by R. G. Cooks and R. B. Cody at the January 2005 ASMS Sanibel Conference. DESI and DART are considered as pioneer techniques in the field of ambient ionization, since they operate in the open laboratory environment and do not require sample pretreatment. In contrast to the liquid spray used by DESI, the ionizing gas from the DART ion source contains a dry stream containing excited state species.
Sources: en.wikipedia.org
=== Beginnings === In September 1935, British chocolate manufacturer Rowntree's brought the first aerated chocolate, Aero, to market. At the time, Rowntree's had been struggling for several years to compete with rival chocolate maker Cadbury's Cadbury Dairy Milk and was looking for a new product to gain an advantage. The new chocolate was the outcome of significant research focused on developing a "count line" chocolate inspired by the recent introduction of the Mars bar to the UK market. Rowntree's patented their aerated chocolate broadly, covering variants such as chocolate with inclusions. As it was released to market, the new chocolate garnered strong sales and positive reviews, although some concerns were voiced within Rowntree's that the product would be a novelty. In their initial marketing, Rowntree's promoted aerated chocolate as better than solid chocolate: more digestible and lacking its "cloying after-taste". Cadbury objected to this and petitioned Rowntree's to stop denigrating rival chocolate makers in marketing.Rival chocolate markers attempted to position their existing product lines as competition (Cadbury their crumbly Flake bars, and Fry's their aerated-honeycomb-filled Crunchie bars), but none were seen by customers as "aerated" in the same sense as Aero. Further to their objections about aerated chocolate's digestibility, Cadbury contested the validity of the patent itself, arguing it overstepped and covered chocolates Cadbury already manufactured, as well as being malformed.
===== MeSH D08.811.277.656 – peptide hydrolases (EC 3.4) ===== MeSH D08.811.277.656.149 – atp-dependent proteases MeSH D08.811.277.656.149.200 – endopeptidase clp MeSH D08.811.277.656.149.500 – protease la MeSH D08.811.277.656.300 – endopeptidases MeSH D08.811.277.656.300.066 – aspartic endopeptidases MeSH D08.811.277.656.300.066.180 – cathepsin d MeSH D08.811.277.656.300.066.185 – cathepsin e MeSH D08.811.277.656.300.066.200 – chymosin MeSH D08.811.277.656.300.066.340 – HIV protease MeSH D08.811.277.656.300.066.700 – pepsin a MeSH D08.811.277.656.300.066.780 – renin MeSH D08.811.277.656.300.099 – brinolase MeSH D08.811.277.656.300.133 – cathepsins MeSH D08.811.277.656.300.133.062 – carboxypeptidase c MeSH D08.811.277.656.300.133.125 – cathepsin b MeSH D08.811.277.656.300.133.187 – cathepsin d MeSH D08.811.277.656.300.133.250 – cathepsin e MeSH D08.811.277.656.300.133.375 – dipeptidyl peptidase i MeSH D08.811.277.656.300.174 – coagulase MeSH D08.811.277.656.300.215 – cysteine endopeptidases MeSH D08.811.277.656.300.215.096 – bromelains MeSH D08.811.277.656.300.215.120 – calpain MeSH D08.811.277.656.300.215.126 – caspases MeSH D08.811.277.656.300.215.126.200 – caspase 1 MeSH D08.811.277.656.300.215.133 – cathepsin b MeSH D08.811.277.656.300.215.160 – chymopapain MeSH D08.811.277.656.300.215.350 – ficain MeSH D08.811.277.656.300.215.585 – papain MeSH D08.811.277.656.300.480 – metalloendopeptidases MeSH D08.811.277.656.300.480.205 – collagenases MeSH D08.811.277.656.300.480.205.352 – gelatinase a MeSH D08.811.277.656.300.480.205.360 – gelatinase b MeSH D08.811.277.656.300.480.205.410 – interstitial collagenase MeSH D08.811.277.656.300.480.205.500 – microbial collagenase MeSH D08.811.277.656.300.480.205.615 – neutrophil collagenase MeSH D08.811.277.656.300.480.252 – gelatinases MeSH D08.811.277.656.300.480.252.420 – gelatinase a MeSH D08.811.277.656.300.480.252.445 – gelatinase b MeSH D08.811.277.656.300.480.300 – insulysin MeSH D08.811.277.656.300.480.452 – lysostaphin MeSH D08.811.277.656.300.480.525 – matrix metalloproteinases MeSH D08.811.277.656.300.480.525.352 – gelatinase a MeSH D08.811.277.656.300.480.525.360 – gelatinase b MeSH D08.811.277.656.300.480.525.451 – interstitial collagenase MeSH D08.811.277.656.300.480.525.505 – matrilysin MeSH D08.811.277.656.300.480.525.615 – neutrophil collagenase MeSH D08.811.277.656.300.480.525.810 – stromelysin 1 MeSH D08.811.277.656.300.480.600 – neprilysin MeSH D08.811.277.656.300.480.632 – pregnancy-associated plasma protein-a MeSH D08.811.277.656.300.480.664 – procollagen n-endopeptidase MeSH D08.811.277.656.300.480.680 – pronase MeSH D08.811.277.656.300.480.827 – thermolysin MeSH D08.811.277.656.300.760 – serine endopeptidases MeSH D08.811.277.656.300.760.030 – acrosin MeSH D08.811.277.656.300.760.176 – chymotrypsin MeSH D08.811.277.656.300.760.198 – complement factor b MeSH D08.811.277.656.300.760.200 – complement factor d MeSH D08.811.277.656.300.760.210 – complement factor i MeSH D08.811.277.656.300.760.228 – endopeptidase clp MeSH D08.811.277.656.300.760.247 – endopeptidase k MeSH D08.811.277.656.300.760.284 – enteropeptidase MeSH D08.811.277.656.300.760.300 – factor viia MeSH D08.811.277.656.300.760.310 – factor ixa MeSH D08.811.277.656.300.760.315 – factor xa MeSH D08.811.277.656.300.760.320 – factor xia MeSH D08.811.277.656.300.760.324 – factor xiia MeSH D08.811.277.656.300.760.353 – furin MeSH D08.811.277.656.300.760.442 – kallikreins MeSH D08.811.277.656.300.760.442.700 – plasma kallikrein MeSH D08.811.277.656.300.760.442.725 – prekallikrein MeSH D08.811.277.656.300.760.442.750 – prostate-specific antigen MeSH D08.811.277.656.300.760.442.875 – tissue kallikreins MeSH D08.811.277.656.300.760.501 – mannose-binding protein-associated serine proteases MeSH D08.811.277.656.300.760.560 – pancreatic elastase MeSH D08.811.277.656.300.760.560.500 – leukocyte elastase MeSH D08.811.277.656.300.760.625 – plasmin MeSH D08.811.277.656.300.760.635 – plasminogen activators MeSH D08.811.277.656.300.760.635.075 – anistreplase MeSH D08.811.277.656.300.760.640 – proprotein convertase 1 MeSH D08.811.277.656.300.760.646 – proprotein convertase 2 MeSH D08.811.277.656.300.760.648 – proprotein convertase 5 MeSH D08.811.277.656.300.760.680 – pronase MeSH D08.811.277.656.300.760.733 – protease la MeSH D08.811.277.656.300.760.787 – subtilisins MeSH D08.811.277.656.300.760.787.805 – subtilisin MeSH D08.811.277.656.300.760.855 – thrombin MeSH D08.811.277.656.300.760.875 – tissue plasminogen activator MeSH D08.811.277.656.300.760.895 – trypsin MeSH D08.811.277.656.300.760.910 – urinary plasminogen activator MeSH D08.811.277.656.300.760.955 – venombin a MeSH D08.811.277.656.300.760.955.060 – ancrod MeSH D08.811.277.656.300.760.955.135 – batroxobin MeSH D08.811.277.656.300.775 – streptokinase MeSH D08.811.277.656.300.775.075 – anistreplase MeSH D08.811.277.656.300.775.900 – streptodornase and streptokinase MeSH D08.811.277.656.350 – exopeptidases MeSH D08.811.277.656.350.100 – aminopeptidases MeSH D08.811.277.656.350.100.150 – amino acid naphthylamidases MeSH D08.811.277.656.350.100.150.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.100.160 – antigens, cd13 MeSH D08.811.277.656.350.100.235 – cystinyl aminopeptidase MeSH D08.811.277.656.350.100.373 – glutamyl aminopeptidase MeSH D08.811.277.656.350.100.511 – leucyl aminopeptidase MeSH D08.811.277.656.350.100.511.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.100.755 – pyroglutamyl-peptidase I MeSH D08.811.277.656.350.245 – carboxypeptidases MeSH D08.811.277.656.350.245.055 – carboxypeptidases A MeSH D08.811.277.656.350.245.083 – carboxypeptidase B MeSH D08.811.277.656.350.245.111 – carboxypeptidase C MeSH D08.811.277.656.350.245.167 – carboxypeptidase H MeSH D08.811.277.656.350.245.224 – carboxypeptidase U MeSH D08.811.277.656.350.245.252 – Serine-type D-Ala-D-Ala carboxypeptidase MeSH D08.811.277.656.350.245.280 – gamma-glutamyl hydrolase MeSH D08.811.277.656.350.245.400 – glutamate carboxypeptidase ii MeSH D08.811.277.656.350.245.450 – lysine carboxypeptidase MeSH D08.811.277.656.350.245.500 – muramoylpentapeptide carboxypeptidase MeSH D08.811.277.656.350.297 – dipeptidases MeSH D08.811.277.656.350.350 – dipeptidyl peptidases MeSH D08.811.277.656.350.350.126 – antigens, cd26 MeSH D08.811.277.656.350.350.375 – dipeptidyl peptidase i MeSH D08.811.277.656.350.555 – metalloexopeptidases MeSH D08.811.277.656.350.555.100 – antigens, cd13 MeSH D08.811.277.656.350.555.200 – carboxypeptidase b MeSH D08.811.277.656.350.555.250 – carboxypeptidase h MeSH D08.811.277.656.350.555.300 – carboxypeptidase u MeSH D08.811.277.656.350.555.350 – carboxypeptidases a MeSH D08.811.277.656.350.555.400 – cystinyl aminopeptidase MeSH D08.811.277.656.350.555.500 – glutamate carboxypeptidase ii MeSH D08.811.277.656.350.555.600 – glutamyl aminopeptidase MeSH D08.811.277.656.350.555.700 – leucyl aminopeptidase MeSH D08.811.277.656.350.555.700.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.555.750 – lysine carboxypeptidase MeSH D08.811.277.656.350.700 – peptidyl-dipeptidase a MeSH D08.811.277.656.675 – metalloproteases MeSH D08.811.277.656.675.374 – metalloendopeptidases MeSH D08.811.277.656.675.374.102 – adam proteins MeSH D08.811.277.656.675.374.205 – collagenases MeSH D08.811.277.656.675.374.205.352 – gelatinase a MeSH D08.811.277.656.675.374.205.360 – gelatinase b MeSH D08.811.277.656.675.374.205.410 – interstitial collagenase MeSH D08.811.277.656.675.374.205.500 – microbial collagenase MeSH D08.811.277.656.675.374.205.615 – neutrophil collagenase MeSH D08.811.277.656.675.374.252 – gelatinases MeSH D08.811.277.656.675.374.252.420 – gelatinase a MeSH D08.811.277.656.675.374.252.445 – gelatinase b MeSH D08.811.277.656.675.374.300 – insulysin MeSH D08.811.277.656.675.374.452 – lysostaphin MeSH D08.811.277.656.675.374.525 – matrix metalloproteinases MeSH D08.811.277.656.675.374.525.352 – gelatinase a MeSH D08.811.277.656.675.374.525.360 – gelatinase b MeSH D08.811.277.656.675.374.525.451 – interstitial collagenase MeSH D08.811.277.656.675.374.525.505 – matrilysin MeSH D08.811.277.656.675.374.525.615 – neutrophil collagenase MeSH D08.811.277.656.675.374.525.810 – stromelysin 1 MeSH D08.811.277.656.675.374.600 – neprilysin MeSH D08.811.277.656.675.374.632 – pregnancy-associated plasma protein-a MeSH D08.811.277.656.675.374.664 – procollagen n-endopeptidase MeSH D08.811.277.656.675.374.680 – pronase MeSH D08.811.277.656.675.374.827 – thermolysin MeSH D08.811.277.656.675.555 – metalloexopeptidases MeSH D08.811.277.656.675.555.100 – antigens, cd13 MeSH D08.811.277.656.675.555.200 – carboxypeptidase b MeSH D08.811.277.656.675.555.250 – carboxypeptidase h MeSH D08.811.277.656.675.555.300 – carboxypeptidase u MeSH D08.811.277.656.675.555.350 – carboxypeptidases a MeSH D08.811.277.656.675.555.400 – cystinyl aminopeptidase MeSH D08.811.277.656.675.555.500 – glutamate carboxypeptidase ii MeSH D08.811.277.656.675.555.600 – glutamyl aminopeptidase MeSH D08.811.277.656.675.555.700 – leucyl aminopeptidase MeSH D08.811.277.656.675.555.700.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.675.555.750 – lysine carboxypeptidase MeSH D08.811.277.656.837 – proprotein convertases MeSH D08.811.277.656.837.124 – carboxypeptidase h MeSH D08.811.277.656.837.186 – carboxypeptidase u MeSH D08.811.277.656.837.249 – furin MeSH D08.811.277.656.837.500 – proprotein convertase 1 MeSH D08.811.277.656.837.562 – proprotein convertase 2 MeSH D08.811.277.656.837.625 – proprotein convertase 5 MeSH D08.811.277.656.837.750 – renin MeSH D08.811.277.656.918 – proteasome endopeptidase complex
== Prime Minister of Thailand (2024–2025) == Following the removal of Srettha as prime minister by the Constitutional Court of Thailand on 14 August 2024, Paetongtarn was nominated by Pheu Thai to succeed him. Her nomination was approved by the House of Representatives on 16 August after no alternatives were named by the other parties in the ruling coalition, making her the youngest person and the second woman to become Prime Minister of Thailand. She was officially sworn in on 18 August following an endorsement from King Vajiralongkorn, followed by her cabinet on 6 September. Her premiership has been plagued by the return of her father Thaksin Shinawatra, a prominent and highly controversial political figure of Thailand. This led to a vote of no-confidence by the opposition, alleging that she has allowed her father to control the Thai government and does not have her own autonomy to run the country – Paetongtarn survived this and remained in position.
Skin-patch testing may also be used to determine whether an individual will experience a hypersensitivity reaction to abacavir, although some patients susceptible to developing AHS may not react to the patch test. The development of suspected hypersensitivity reactions to abacavir requires immediate and permanent discontinuation of abacavir therapy in all patients, including patients who do not possess the HLA-B*5701 allele. On 1 March 2011, the FDA informed the public about an ongoing safety review of abacavir and a possible increased risk of heart attack associated with the drug. A meta-analysis of 26 studies conducted by the FDA, however, did not find any association between abacavir use and heart attack
=== Site hosting === Planet Half-Life also offered free web hosting for Half-Life themed websites. The web hosting was regulated through GameSpy, though the address of hosted sites were subsets of the Planet Half-Life domain. This was a major attraction of the site in its early days and many original Half-Life mod teams took advantage of the offer. However this feature has not been utilized nearly as much since the release of Half-Life 2. A directory of the old sites still exists, although most have been abandoned by their creators.
Sources: en.wikipedia.org
==== Implications for cardiovascular disease and therapy ==== Understanding VEGF's intracrine role in the heart opens new avenues for therapeutic intervention in cardiovascular diseases. Unlike traditional VEGF-targeted therapies that focus on extracellular angiogenesis, modulating intracrine VEGF could provide a more cell-specific approach to enhancing cardiac repair and regeneration. Targeting intracrine VEGF pathways may offer novel strategies for treating ischemic heart disease, heart failure, and other cardiovascular pathologies where vascular dysfunction is a contributing factor. In conclusion, VEGF functions not only as an extracellular angiogenic factor but also as an intracrine regulator of cardiac cell survival and development. Future research into intracrine VEGF mechanisms may provide critical insights into cardiac regeneration and the development of more effective cardiovascular therapies.
=== 2018 presidential election === In 2017, Peña ran for the Colorado Party's presidential candidacy in the 2018 general election, ultimately losing out to Mario Abdo Benítez, with Abdo Benítez winning 564,811 votes (50.93%) to Peña's 480,114 (43.29%). Following his defeat in the Colorado Party's internal elections in 2017, Peña was elected to the board of Banco Amambay in March 2018. The bank was part of the Cartes Group, which was owned by former President of Paraguay Horacio Cartes, for whom Peña had served as minister of finance.
World War II was a global military conflict that took place in 1939–1945. It was the largest and deadliest war in history, culminating in The Holocaust and ending with the dropping of the atom bomb. Although Japan had invaded China in 1937, the conventional view is that World War II began on 1 September 1939, when Nazi Germany invaded Poland. Within two days, the United Kingdom and France declared war on Germany, even though the fighting was confined to Poland. Pursuant to a then-secret provision of its non-aggression Molotov–Ribbentrop Pact, the Soviet Union joined Germany on 17 September 1939, to conquer Poland and divide Eastern Europe. The Allies were initially made up of Poland, the United Kingdom, France, Australia, Canada, New Zealand, South Africa, as well as British Commonwealth countries which were controlled directly by the UK, such as the Indian Empire. All of these countries declared war on Germany in September 1939. Following the lull in fighting, known as the "Phoney War", Germany invaded western Europe in May 1940. Six weeks later, France, in the meantime attacked by Italy as well, surrendered to Germany, which then tried unsuccessfully to conquer Britain. On 27 September, Germany, Italy, and Japan signed a mutual defense agreement, the Tripartite Pact, and were known as the Axis powers. Nine months later, on 22 June 1941, Germany launched a massive invasion of the Soviet Union, which prompted it to join the Allies. Germany was now engaged in fighting a war on two fronts.
== Chemistry == Chlorphenamine is an alkylamine and is a part of a series of antihistamines including pheniramine (Naphcon) and its halogenated derivatives including fluorpheniramine, dexchlorphenamine (Polaramine), brompheniramine (Dimetapp), dexbrompheniramine (Drixoral), deschlorpheniramine, and iodopheniramine. The halogenated alkylamine antihistamines all exhibit optical isomerism, and chlorphenamine in the indicated products is racemic chlorphenamine maleate, whereas dexchlorphenamine is the dextrorotary stereoisomer.
Brassinosteroids (BRs) are a class of polyhydroxysteroids, the only example of steroid-based hormones in plants. Brassinosteroids control cell elongation and division, gravitropism, resistance to stress, and xylem differentiation. They inhibit root growth and leaf abscission. Brassinolide was the first brassinosteroid to be identified and was isolated from extracts of rapeseed (Brassica napus) pollen in 1979. Brassinosteroids are a class of steroidal phytohormones in plants that regulate numerous physiological processes. This plant hormone was identified by Mitchell et al. who extracted ingredients from Brassica pollen only to find that the extracted ingredients' main active component was Brassinolide. This finding meant the discovery of a new class of plant hormones called Brassinosteroids. These hormones act very similarly to animal steroidal hormones by promoting growth and development. In plants these steroidal hormones play an important role in cell elongation via BR signaling. The brassinosteroids receptor brassinosteroid insensitive 1 (BRI1) is the main receptor for this signaling pathway. This BRI1 receptor was found by Clouse et al. who made the discovery by inhibiting BR and comparing it to the wildtype in Arabidopsis. The BRI1 mutant displayed several problems associated with growth and development such as dwarfism, reduced cell elongation and other physical alterations. These findings mean that plants properly expressing brassinosteroids grow more than their mutant counterparts.
Sources: en.wikipedia.org
It is a tripeptide of glutamate, cysteine, and glycine. The glutamate-cysteine bond is unusual because it forms through the gamma-carboxyl group.
It reflects the balance between oxidant exposure and antioxidant capacity. The ratio is not a direct clinical diagnosis and depends on the tissue and sample method.
No. It also participates in detoxification, amino acid transport, and protein modification. Its roles vary by cell type and compartment.
Common methods include spectrophotometric enzyme cycling assays, HPLC with UV or fluorescence detection, and LC-MS/MS. Detection often requires derivatization because glutathione lacks a strong chromophore. Method choice depends on the sample type and the required sensitivity.